Kymera Therapeutics (KYMR) Projected to Post Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is expected to be releasing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Kymera Therapeutics to post earnings of ($0.73) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.58) earnings per share. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $61.95 on Wednesday. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $63.96. The stock’s 50-day moving average is $51.34 and its two-hundred day moving average is $43.29. The stock has a market cap of $4.43 billion, a PE ratio of -17.85 and a beta of 2.26.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 79,220 shares of the stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the transaction, the chief financial officer owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $59.19, for a total value of $295,950.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 176,910 shares of company stock worth $9,572,948. Company insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Osaic Holdings Inc. lifted its holdings in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Kymera Therapeutics during the 2nd quarter worth approximately $218,000. Tower Research Capital LLC TRC lifted its holdings in Kymera Therapeutics by 111.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,425 shares of the company’s stock worth $237,000 after buying an additional 2,858 shares during the last quarter. Vident Advisory LLC bought a new position in Kymera Therapeutics during the 2nd quarter worth approximately $376,000. Finally, Oxford Asset Management LLP bought a new position in Kymera Therapeutics during the 2nd quarter worth approximately $201,000.

Analysts Set New Price Targets

Several equities analysts recently commented on KYMR shares. HC Wainwright boosted their price target on Kymera Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Oppenheimer boosted their price target on Kymera Therapeutics from $53.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada started coverage on Kymera Therapeutics in a research report on Tuesday, September 16th. They set an “outperform” rating and a $70.00 price target on the stock. The Goldman Sachs Group raised Kymera Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. Finally, Barclays started coverage on Kymera Therapeutics in a research report on Wednesday, September 17th. They set an “overweight” rating and a $60.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $65.45.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.